Science & Enterprise subscription

Follow us on Twitter

  • New post on Science and Enterprise: Microrobot Swarm Breaks Up Bacterial Biofilms https://t.co/ZWjbJxJqos #Science #Business
    about 1 hour ago
  • After Pentagon Ends Contract, Top-Secret Scientists Group Vows To Carry On https://t.co/G5ClsQowD4 ... "We're very… https://t.co/hnp3WNu72G
    about 15 hours ago
  • Hospital, academic, and industry researchers devised automated techniques including artificial intelligence to shar… https://t.co/fxOi8PJ92w
    about 19 hours ago
  • New post on Science and Enterprise: A.I. Speeds Infant Genetic Disease Diagnostics https://t.co/Evo7kiqixY #Science #Business
    about 19 hours ago
  • A neuroscience lab created a virtual speech-generating vocal system that produces natural sounding human speech by… https://t.co/ShpRjzEWSk
    about 1 day ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Company, Charity to Discover Antibiotic Boosters

MRSA bacteria

MRSA bacteria ( National Institute of Allergy and Infectious Diseases)

11 July 2016. An advocacy organization promoting research on drug-resistant bacteria is collaborating with a drug discovery company to find compounds that reverse resistance to antibiotics. Financial details about the contract between Antibiotic Research UK in York and Evotec AG in Hamburg were not disclosed.

Antibiotic resistance in bacteria is a growing, worldwide problem that World Health Organization calls a “serious threat to global public health that requires action across all government sectors and society.” Many hospital-acquired infections are resistant to antibiotics, such as methicillin-resistant Staphylococcus aureus or MRSA, with the problem found increasingly among individuals with HIV and tuberculosis. WHO reported in 2013, some 480 000 new cases of multidrug-resistant tuberculosis were identified in about 100 countries.

Antibiotic Research UK is an advocacy and charitable organization formed in June 2014 from an informal network of academic researchers and clinicians concerned about the low priority seemingly given research on antibiotic-resistant bacteria and the lack of new drugs. A paper published in September 2014 in The Lancet Infectious Diseases found £95 million ($US 123 million) spent on studies of antibiotics, accounting for only 0.7 percent of all medical research funding in the U.K. The organization aims to raise £30 million in the next 5 years to bring at least 1 new antibiotic treatment to the market.

Evotec offers drug discovery services in the areas of neuroscience, pain, metabolic diseases, oncology, inflammation, and infectious diseases. The company generally works through collaborations with research labs, not-for-profit organizations, and drug companies, providing target identification and validation, hit identification, and candidate development including biologics.

Under the agreement, Antibiotic Research UK and Evotec will partner on discovery of so-called antibiotic resistance breakers, existing drugs that when combined with antibiotics can kill gram-negative bacteria directly or break the defense mechanisms in bacteria providing resistance. Gram-negative bacteria are associated with infections such as pneumonia, bloodstream infections, wound, and surgical site infections. “Gram” refers to a classification for bacteria where the microbes either retain (gram-positive) or shed (gram-negative) a test stain on their protective cell coatings.

The joint initiative is the first research project undertaken by Antibiotic Research UK since its founding. Much of the work is expected to take place at Evotec’s research site in Manchester, U.K. that specializes in infectious diseases and the company’s bio-safety certified high-throughput screening facility in Toulouse, France.

Read more:

*     *     *

Please share Science & Enterprise ...

Comments are closed.